Loading
A phase 3 trial of Toripalimab, Gemcitabine, Carboplatin and Cisplatin in bladder & urothelial cancer, run by Mabwell (Shanghai) Bioscience Co., Ltd., now recruiting.
9MW2821 in Combination With Toripalimab vs Standard Chemotherapy in Locally Advanced or Metastatic Urothelial Cancer is a phase 3 interventional study registered as NCT06592326 by Mabwell (Shanghai) Bioscience Co., Ltd., with 460 participants planned, started 2024-08-22 and due to reach its primary completion in 2027-09. Interventions recorded: 9MW2821, Toripalimab, Gemcitabine and Cisplatin/Carboplatin.
Shares Mabwell (Shanghai) Bioscience, Muscle-invasive and advanced bladder cancer, Toripalimab, Bladder & urothelial cancer and the tag pipeline.
Shares Mabwell (Shanghai) Bioscience, Muscle-invasive and advanced bladder cancer, Toripalimab, Bladder & urothelial cancer and the tag pipeline.
Shares Muscle-invasive and advanced bladder cancer, Toripalimab, Gemcitabine, Bladder & urothelial cancer and the tag pipeline.
Shares Mabwell (Shanghai) Bioscience, Toripalimab, Bladder & urothelial cancer, Immune checkpoint inhibitors and the tag pipeline.
Shares Muscle-invasive and advanced bladder cancer, Gemcitabine, Bladder & urothelial cancer, Cisplatin and the tag pipeline.
Shares Mabwell (Shanghai) Bioscience, Muscle-invasive and advanced bladder cancer, Bladder & urothelial cancer and the tag pipeline.
Shares Muscle-invasive and advanced bladder cancer, Gemcitabine, Bladder & urothelial cancer, Cisplatin and the tag pipeline.
Shares Muscle-invasive and advanced bladder cancer, Gemcitabine, Bladder & urothelial cancer, Cisplatin and the tag pipeline.